Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 8:16 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 439 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Multiple Sclerosis Relapse Clear all

Conditions: Multiple Sclerosis
Interventions: Adrenocorticotropic Hormone; Drug
Lead sponsor: State University of New York at Buffalo; Other
Eligibility: 18 Years to 65 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: alemtuzumab; Biological
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: Not listed
Enrollment: 1,314 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2016
U.S. locations: 69
States / cities: Cullman, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 60 more

Conditions: Multiple Sclerosis (MS) - Relapsing-remitting, Multiple Sclerosis (MS) Secondary Progressive, Multiple Sclerosis (MS) Primary Progressive
Interventions: Remibrutinib (Open Label); Drug
Lead sponsor: Moein Amin; Other
Eligibility: 18 Years to 60 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2030
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Relapsing Multiple Sclerosis, Multiple Sclerosis
Interventions: Cerebrospinal and Blood Serum Semaphorin 4A Levels; Diagnostic Test
Lead sponsor: Providence Health & Services; Other
Eligibility: 18 Years to 55 Years · Female only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Relapsing Multiple Scelrosis
Interventions: Ofatumumab subcutaneous injection, Teriflunomide-matching placebo capsules, Teriflunomide capsule, Matching placebo of ofatumumab subcutaneous injections; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 955 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 59
States / cities: Birmingham, Alabama • Cullman, Alabama • Tucson, Arizona + 51 more

Conditions: Multiple Sclerosis
Interventions: Not listed
Lead sponsor: Biogen; Industry
Eligibility: 18 Years and older
Enrollment: 2,978 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 38
States / cities: Homewood, Alabama • Gilbert, Arizona • Hanford, California + 33 more

Conditions: Multiple Sclerosis, Relapsing-Remitting, Clinically Isolated Syndrome
Interventions: Tovaxin; Biological
Lead sponsor: Opexa Therapeutics, Inc.; Industry
Eligibility: Not listed
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 27
States / cities: Cullman, Alabama • Phoenix, Arizona • Berkeley, California + 23 more

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: abatacept, Placebo; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 20
States / cities: Phonix, Arizona • Berkeley, California • Los Angeles, California + 17 more

Conditions: Multiple Sclerosis
Interventions: ABT-555, Placebo; Drug · Other
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 8
States / cities: Orlando, Florida • Lenexa, Kansas • Baltimore, Maryland + 5 more

Conditions: Multiple Sclerosis, Tomography, Optical Coherence, Retinal Degeneration, Visual Acuity
Interventions: Ofatumumab; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Relapsing Forms of Multiple Sclerosis
Interventions: Fingolimod, Standard MS DMTs; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 1,053 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 142
States / cities: Birmingham, Alabama • Cullman, Alabama • Phoenix, Arizona + 125 more

Conditions: Multiple Sclerosis (MS)
Interventions: Fingolimod, Ofatumumab, Siponimod, Fingolimod placebo, Siponimod placebo, Ofatumumab placebo; Drug · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 10 Years to 17 Years
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2031
U.S. locations: 6
States / cities: Little Rock, Arkansas • Los Angeles, California • Washington D.C., District of Columbia + 3 more

Conditions: Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis
Interventions: Guanabenz; Drug
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: 18 Years to 55 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Clinically Isolated Syndrome, Relapsing Remitting Multiple Sclerosis
Interventions: Therapeutic diet and lifestyle; Behavioral
Lead sponsor: Terry L. Wahls; Other
Eligibility: 18 Years to 55 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
Interventions: Tetanus, diphtheria, and acellular pertussis vaccine, Pneumococcal polysaccharide vaccine, Seasonal influenza vaccine; Biological
Lead sponsor: Celgene; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 29
States / cities: Palo Alto, California • Colorado Springs, Colorado • Southington, Connecticut + 26 more

Conditions: Relapsing-Remitting Multiple Sclerosis
Interventions: IFN-β-1a (Rebif®); Drug
Lead sponsor: Waukesha Memorial Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Waukesha, Wisconsin

Conditions: Relapsing Remitting Multiple Sclerosis
Interventions: Interferon beta 1-a, glatiramer acetate, placebo; Drug · Other
Lead sponsor: Fred Lublin; Other
Eligibility: 18 Years to 60 Years
Enrollment: 1,008 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2013
U.S. locations: 67
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 55 more

Conditions: Relapsing Multiple Sclerosis
Interventions: Interferon beta-1a, Ocrelizumab-matching placebo, Ocrelizumab, Interferon beta-1a-matching placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 835 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2022
U.S. locations: 48
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 43 more

Conditions: Multiple Sclerosis
Interventions: repository corticotropin injection, Saline; Drug
Lead sponsor: University at Buffalo; Other
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Relapsing Remitting Multiple Sclerosis
Interventions: Not listed
Lead sponsor: Washington Neuropsychology Research Group; Other
Eligibility: 25 Years to 50 Years
Enrollment: 1 participant
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 7
States / cities: Berkely, California • Lexington, Kentucky • Springfield, Massachusetts + 4 more

Conditions: Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
Interventions: Bazedoxifene Acetate; Drug
Lead sponsor: Riley Bove, MD; Other
Eligibility: 40 Years to 65 Years · Female only
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Relapsing Remitting Multiple Sclerosis
Interventions: placebo, orelabrutinib; Other · Drug
Lead sponsor: Beijing InnoCare Pharma Tech Co., Ltd.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 5
States / cities: Ormond Beach, Florida • Tampa, Florida • Northbrook, Illinois + 2 more

Conditions: Multiple Sclerosis
Interventions: Tecfidera; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Relapsing Multiple Sclerosis (RMS)
Interventions: Ublituximab, Teriflunomide, Oral Placebo, IV Placebo; Biological · Drug
Lead sponsor: TG Therapeutics, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 545 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 13
States / cities: Phoenix, Arizona • Aurora, Colorado • Tampa, Florida + 10 more

Search by objective public record fields.

Effects of Acthar on Recovery From Cognitive Relapses in MS

An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab

A Study of Remibrutinib Using MR Imaging in Relapsing or Progressive MS

Sema 4A as a Marker for Inflammatory Disease in Multiple Sclerosis

Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis.

Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS)

Open Label Extension of Prior TERMS Study to Treat Relapsing Forms of Multiple Sclerosis

A Cooperative Clinical Study of Abatacept in Multiple Sclerosis

A Multiple Dose Study of ABT-555 in Subjects With Relapsing Forms of Multiple Sclerosis

Retinal Atrophy and Neurofilament Light Chain in People With Multiple Sclerosis Taking Ofatumumab

A 6-month, Randomized, Open-label, Patient OutComes, Safety and Tolerability Study of Fingolimod (FTY720) 0.5 mg/Day vs. Comparator in Patients With Relapsing Forms of Multiple Sclerosis

Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis

Oral Guanabenz for Multiple Sclerosis

Clinically Isolated Syndrome and Relapsing-Remitting Multiple Sclerosis

Safety Study to Evaluate Immune Response of Vaccines in Participants With Relapsing Forms of Multiple Sclerosis Who Receive Ozanimod Compared to Non-Pegylated Interferon (IFN)-β or No Disease Modifying Therapy

fMRI Study of Treatment Recommendations Comparing Recently Diagnosed Multiple Sclerosis (MS) Patients to Controls

Combination Therapy in Patients With Relapsing-Remitting Multiple Sclerosis (MS)CombiRx

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis

Effect of Adrenocorticotropin Injection With Weekly Interferon Beta in Patients With Relapsing Remitting Multiple Sclerosis (MS)

Comparison of Campath and Rebif Treatment on Cognition in Multiple Sclerosis (MS)

Bazedoxifene Acetate as a Remyelinating Agent in Multiple Sclerosis

A Phase 2 Study of Orelabrutinib in Patients With Relapsing-Remitting Multiple Sclerosis

Restoring Glutathione Synthesis With Tecfidera: An in Vivo H-MRS Single-Arm Study at 7T in Patients With RR MS

Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS)